Early Detection
438 articles
The ABCs of Genetic Testing
There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.
Neoantigens Provide New Hope for Pancreatic Cancer Treatments
Vinod Balachandran’s team identified increased T cells in the tumors of long-term pancreatic cancer survivors, with a role for neoantigens in immunotherapy.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
The Promise of Organoids
Dr. Brian Wolpin explains how organoids are being used to develop personalized treatment for pancreatic cancer patients.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders–patients who respond extremely well to chemotherapy–for treatment clues.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
Dr. Michael Pishvaian explains how platinum-based therapy can improve the survival of pancreatic cancer patients with a specific mutation.
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O’Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Harnessing the Power of Radionuclide Therapy
Julie Sutcliffe is working with targeted radionuclide therapy to go after pancreatic cancer cells that have spread beyond the pancreas.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
For Pancreatic Cancer Patients, Pain Control Through Targeted Radiotherapy
Dr. Yaacov Lawrence is using celiac plexus radiotherapy in a clinical trials to target a source of pain for pancreatic cancer patients.